Des approches de bio-conjugaison pour l'amélioration des thérapies protéiques

 

Marc Andre Gauthier

Institut national de la recherche scientifique [INRS]

 

Domaine : matériaux

Programme Chercheurs-boursiers - Junior 2

Concours 2019-2020

Approximately 25% of all new drugs approved by the American Food and Drug Administration are proteins. Unfortunately, proteins possess a certain number of intrinsic shortcomings related to the structure and chemistry that limit their efficacy as drugs. My research program takes a translational approach to medical research and exploits innovations in polymer and bioconjugate chemistry and uses them as tools for optimizing therapies for various prominent and rare diseases.

In one project, we seek to reduce allergic responses towards a protein drug used in the treatment of acute lymphoblastic leukemia. In a second project, we seek to improve the treatment of the relapsed form of this disease, by developing a drug that redirects the immune system to kill cancer cells. In the last project, we seek to improve the treatment of stroke, by developing a drug that protects the brain from toxic substances that accumulate in this area. Overall, our research program develops better therapies that will improve the quality of life of the population of Quebec/Canada and to reduce the financial burden of healthcare on society.